Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afinitor + Paclitaxel + Carboplatin in Advanced Gastric Cancer
NCT01514110Phase 2Completed
- Sponsor
- The Chinese University of Hong Kong
- Start
- Jan 2008
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of everolimus in gastric cancer (GC), sponsored by The Chinese University of Hong Kong. Primary endpoints: Maximum Tolerated Dose at 2 years and Dose Limiting Toxicities at 2 years. Started Jan 2008; status: completed.
02
Drugs
everolimus
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT01514110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01514110.